FGP
DGX icon

Freestone Grove Partners’s Quest Diagnostics DGX Stock Holding History

Freestone Grove Partners’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.12M Sell
5,690
-303,524
-98% -$59M 0.01% 454
2025
Q4 		$53.7M Buy
+309,214
New +$56.3M 0.39% 71

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Freestone Grove Partners's DGX Position: Q1 2026 in Review

Freestone Grove Partners reduced its Quest Diagnostics (DGX) stake by 98% in Q1 2026, selling an estimated $59M and leaving 5,690 shares worth $1.12M. The position accounts for 0.01% of the portfolio, ranked #454.

Freestone Grove Partners first reported a position in DGX in Q4 2025 and has held it in 2 quarters since. The position peaked at $53.7M in Q4 2025. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Freestone Grove Partners held 5,690 shares of Quest Diagnostics worth $1.12M as of Q1 2026.
  • Freestone Grove Partners sold 303,524 Quest Diagnostics shares in Q1 2026, an estimated $59M.
  • Quest Diagnostics made up 0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #454 holding.
  • Freestone Grove Partners first reported a position in Quest Diagnostics in Q4 2025 and has held it in 2 quarters since.
  • Freestone Grove Partners's Quest Diagnostics position peaked at $53.7M in Q4 2025.
  • 1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.